Click here to view online

The OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) Neurotrophic Keratitis Roundtable engaged medical experts with experience in the diagnosis and management of neurotrophic keratitis (NK). The goal of the roundtable was to review relevant literature on NK and OXERVATE clinical trial data; identify opportunities to raise NK awareness among clinicians; discuss assessment and therapy of NK; and provide input on the selection of appropriate patients for OXERVATE, a therapy recently approved for the treatment of NK.

Important Safety Information Contact lenses should be removed before applying Oxervate because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration. Oxervate may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their doctor if a more serious eye reaction occurs. The most common adverse reaction was eye pain following instillation which was reported in approximately 16% of patients. Other adverse reactions included corneal deposits, foreign body sensations in the eye, ocular hyperemia (enlarged blood vessels in the white of the eyes), swelling (inflammation) of the eye, and increase of tears (1-10% of patients). The FDA-approved product labeling can be found at www.oxervate.com. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Dompe at USDrugSafety@dompe.com.

© 2019 Dompe U.S. All rights reserved. US-OXE-1900078 09/19.

Forward to a Friend

Dompe US 11 Marina Park Drive #1410 I Boston, MA 02210 I 833-366-7387